MRKR vs. UNCY, CARA, ELDN, CLNN, PMN, NRXP, BCTX, OCUP, RMTI, and BOLT
Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Unicycive Therapeutics (UNCY), Cara Therapeutics (CARA), Eledon Pharmaceuticals (ELDN), Clene (CLNN), ProMIS Neurosciences (PMN), NRx Pharmaceuticals (NRXP), BriaCell Therapeutics (BCTX), Ocuphire Pharma (OCUP), Rockwell Medical (RMTI), and Bolt Biotherapeutics (BOLT). These companies are all part of the "pharmaceutical preparations" industry.
Unicycive Therapeutics (NASDAQ:UNCY) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 42.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 24.1% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Unicycive Therapeutics currently has a consensus target price of $5.30, indicating a potential upside of 409.62%. Given Marker Therapeutics' higher probable upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Marker Therapeutics.
Marker Therapeutics has higher revenue and earnings than Unicycive Therapeutics.
Unicycive Therapeutics has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Marker Therapeutics received 52 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 64.29% of users gave Unicycive Therapeutics an outperform vote while only 63.06% of users gave Marker Therapeutics an outperform vote.
Unicycive Therapeutics has a net margin of 0.00% compared to Unicycive Therapeutics' net margin of -142.62%. Marker Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.
In the previous week, Unicycive Therapeutics' average media sentiment score of 0.67 beat Marker Therapeutics' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the news media.
Summary
Unicycive Therapeutics beats Marker Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Marker Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marker Therapeutics Competitors List
Related Companies and Tools
